

	Application Number	10/542,312
	Filing Date	July 15, 2005
	First Named Inventor	Tidmarsh, George
	Art Unit	1654
	Examiner Name	ABDEL A MOHAMED
	Attorney Docket Number	021305-003610US
Number of Pages in This Submission		768

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (2 pgs) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard Form PTO/SB/08A & B (8 pgs) References: 14, 19, 22-26, 40, 46, 48, 55, 61-62 and 69 (757 pgs)
Remarks: The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Townsend and Townsend and Crew LLP		
Signature			
Printed name	Randolph Ted Apple		
Date	6/29/06	Reg. No.	36,429

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name	Anthony J. Marshall	Date	6/29/06

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PATENT
Attorney Docket No.: 021305-003610US
Client Reference No.: 010-094-USU27



On 6/29/06
TOWNSEND and TOWNSEND and CREW LLP
By: [Signature]
Anthony J. Marshall

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

George TIDMARSH, et al.

Application No.: 10/542,312

Filed: July 15, 2005

For: TREATMENT OF BENIGN
PROSTATIC HYPERPLASIA USING
ENERGOLYTIC AGENTS

Confirmation No.: 8919

Examiner: ABDEL A MOHAMED

Art Unit: 1654

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of references 14, 19, 22-26, 40, 46, 48, 55, 61-62 and 69 are enclosed. In accordance with 37 CFR §1.98(d), copies of the references 13, 15-18, 20-21, 27-39, 41-45, 47, 49-54, 56-60, 63-68 and 70-95 can be found in Application No. 10/759,337, filed January 16, 2004 (Attorney Docket No. 021305-003500US). It is respectfully requested that the cited references be expressly considered during the prosecution of this


application, and the references be made of record therein and appear among the references cited on any patent to issue therefrom.

Reference 40 describes comparative 5-HT4 receptor antagonist activity of LY353433 and its active hydroxylated metabolites. A Pharmaprojects database entry for LY353433 includes the notation "Phase II trials were conducted in urinary incontinence and BPH (Company brochure, Jul 1998)."

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Randolph Ted Apple
Reg. No: 36,429

Date: 6/29/06

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RTA:ajm
60791163 v1



Substitute for form 1449A&B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/542,312
Filing Date	July 15, 2005
First Named Inventor	Tidmarsh, George
Art Unit	1654
Examiner Name	ABDEL A MOHAMED
Attorney Docket Number	021305-003610US

Sheet	1	of	8
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-3,895,026	07-15-1975	PALAZZO, et al.	
	2	US-4,684,627	8/13/1984	LEVEEN, et al.	
	3	US-4,840,939	3/18/1987	LEVEEN, et al.	
	4	US-5,260,327	8/4/1992	KIM, et al.	
	5	US-5,654,320	08-05-1997	CATLOW, et al.	
	6	US-5,827,887	10/27/1998	GOURVEST, et al.	
	7	US-6,001,865	5/4/1999	SILVESTRINI, et al.	
	8	US-6,319,517	8/27/1998	CAVALLO, et al.	
	9	US-6,337,087	8/27/1998	CAVALLO, et al.	
	10	US-6,482,802	11/19/2002	HU, et al.	
	11	US-6,428,968	8/6/2002	MOLNAR-KIMBER, et al.	
	12	US-2005/0234135 A1	10-20-2005	WANG, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	13	IE	54256		08-02-1989	A.C.R.A.F.		<input type="checkbox"/>
	14	WO	92/18132		10-29-1992	MERCK & CO., INC.		<input type="checkbox"/>
	15	WO	96/40142		12-19-1996	PFIZER, INC.		<input type="checkbox"/>
	16	WO	97/14670		04-24-1997	KANOLDT ARZNEIMITTEL HOECHST AKTIENGESSELLSCHAFT		<input type="checkbox"/>
	17	CA	2206198		05-27-1997	ASTA MEDICA		<input type="checkbox"/>
	18	WO	98/10781		03-19-1998	CATLOW, et al.		<input type="checkbox"/>
	19	EP	0732333	B1	08-01-2001	THRESHOLD PHARMACEUTICALS		<input type="checkbox"/>
	20	WO	04/064735		08-05-2004	THRESHOLD PHARMACEUTICALS		<input type="checkbox"/>
	21	WO	04/064736		08-05-2004	POPOWSKI		<input type="checkbox"/>
	22	WO	06/024488	A2	03-09-2006	POPOWSKI		<input type="checkbox"/>
	23	WO	06/024489	A2	03-09-2006	POPOWSKI		<input type="checkbox"/>
	24	WO	06/024490	A2	03-09-2006	POPOWSKI		<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/542,312
				Filing Date	July 15, 2005
				First Named Inventor	Tidmarsh, George
				Art Unit	1654
				Examiner Name	ABDEL A MOHAMED
Sheet	2	of	8	Attorney Docket Number	021305-003610US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	25	WO	06/024491	A2	03-09-2006	POPOWSKI		<input type="checkbox"/>
	26	WO	06/024492	A2	03-09-2006	POPOWSKI		<input type="checkbox"/>
								<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	27	BELZACQ, et al., Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite, and CD437, Oncogene (2001) 20:7579-7587.	<input type="checkbox"/>	
	28	BELZACQ, et al., The denine nucleotide translocator in apoptosis, Biochimie (2002) 84:167-176.	<input type="checkbox"/>	
	29	BENZ, et al., Lactic dehydrogenase isozymes, 31P magnetic resonance spectroscopy, and in vitro antimitochondrial tumor toxicity with gossypol and rhodamine-123, J Clin Invest., 79:517-523.	<input type="checkbox"/>	
	30	BERRUTI, et al., Time to Progression in Metastatic Breast Cancer Patients Treated With Epirubicin Is Not Improved by the Addition of Either Cisplatin or Lonidamine: Final Results of a Phase III Study With a Factorial Design, J. Clin. Oncology (2002) 20(20):4150-4159.	<input type="checkbox"/>	
	31	BESNER, et al., Pharmacokinetics and Metabolism of Lonidamine in Rats: Evidence of Enterohepatic Recycling*, Drug Metabolism Reviews (1997) 29(1&2):219-234.	<input type="checkbox"/>	
	32	BESNER, et al., Pharmacokinetics of Lonidamine after Oral Administration in Cancer Patients, Oncology (1984) 41(suppl. 1):48-52.	<input type="checkbox"/>	
	33	BLOCH, et al., Enhancement of hyperthermic toxicity by lonidamine in the Dunning R3327G rat prostatic adenocarcinoma, Prostate (1994) 24:131-138.	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/542,312
				Filing Date	July 15, 2005
				First Named Inventor	Tidmarsh, George
				Art Unit	1654
				Examiner Name	ABDEL A MOHAMED
Sheet	3	of	8	Attorney Docket Number	021305-003610US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	34	BOCCARDO, et al., Phase II study with lonidamine in the treatment of hormone-refractory prostatic cancer patients, Tumori (1992) 78:137-139.	<input type="checkbox"/>
	35	BUNN, P.A., Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Who, what, When, Why?, J. Clin. Oncology (2002) 20(18s):23s-33s.	<input type="checkbox"/>
	36	CALABRESI, et al., Fluorouracil, Doxorubicin, and Cyclophosphamide Versus Fluorouracil, Doxorubicin, and Cyclophosphamide Plus Lonidamine for the Treatment of Advanced Breast Cancer: A Multicentric Randomized Clinical Study, Seminars in Oncology (1991) 18(2, suppl. 4):66-72.	<input type="checkbox"/>
	37	CASTRO, et al., Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia, Prostate (2004) 60:153-159.	<input type="checkbox"/>
	38	CHANG, Gossypol induces spermidine/spermine N1-acetyltransferase in canine prostate epithelial cells, Biochem Biophys Res Commun. (1997) 231:383-8.	<input type="checkbox"/>
	39	CIONINI, L., Radiotherapy Plus Lonidamine in Non-Small Cell Lung Cancer, Seminars in Oncology (1991) 18(2 suppl. 4):49-52.	<input type="checkbox"/>
	40	COHEN, M. L., et al., Comparative 5-HT ₄ receptor antagonist activity of LY353433 and its active hydroxylated metabolites, Drug Development Research (1998) 43(4):193-199	<input type="checkbox"/>
	41	COLLINS, et al., Benign prostatic stromal cells are regulated by basic fibroblast growth factor and transforming growth factor-beta 1, J Endocrinol. (1996) 151:315-322.	<input type="checkbox"/>
	42	COMELLA, et al., Cisplatin, Gemcitabine, and Vinorelbine Combination Therapy in Advanced Non-Small-Cell Lung Cancer: A Phase II Randomized Study of the Southern Italy Cooperative Oncology Group, J. Clin. Oncology (1999) 17(5):1526-1534.	<input type="checkbox"/>
	43	CORSI, et al., 1-Halobenzyl-1H-indazole-3-carboxylic acids. A New Class of Antispermatogetic Agents, J. Med. Chem. (1976) 19(6):778-783.	<input type="checkbox"/>
	44	COSTELLO, et al., The Intermediary Metabolism of the Prostate: A Key to Understanding the Pathogenesis and Progression of Prostate Malignancy, Oncology (2000) 59:269-282.	<input type="checkbox"/>
	45	COSTELLO, et al., Zinc causes a shift toward citrate at equilibrium of the m-aconitase reaction of prostate mitochondria, J. Inorganic Biochem. (2000) 78:161-165.	<input type="checkbox"/>
Examiner Signature			Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/542,312
				Filing Date	July 15, 2005
				First Named Inventor	Tidmarsh, George
				Art Unit	1654
				Examiner Name	ABDEL A MOHAMED
Sheet	4	of	8	Attorney Docket Number	021305-003610US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	46	COSTELLO, L. C., et al, Testosterone and prolactin regulation of metabolic genes and citrate metabolism of prostate epithelial cells, Hormone and Metabolic Research (2002) 34: 417-424.	<input type="checkbox"/>		
	47	CUNA, et al., Toxicity and Clinical Tolerance of Lonidamine, Seminars in Oncology (1991) 18(2 suppl. 4):18-22.	<input type="checkbox"/>		
	48	Database WPI Section Ch, Week 199921 Derwent Publications Ltd., London GB: Class B05m AN 1999-244786 & CN 1204510 (abstract)	<input type="checkbox"/>		
	49	DELENA, et al., Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer, Eur. J. Cancer (2001) 37:364-368.	<input type="checkbox"/>		
	50	DELENA, et al., Revertant and Potentiating Activity of Lonidamine in Patients With Ovarian Cancer Previously Treated With Platinum, J. Clin. Oncology (1997) 15(10):3208-3213.	<input type="checkbox"/>		
	51	DUDAK, et al., Enhancement of radiation response of prostatic carcinoma by lonidamine, Anticancer Res. (1996) 16:3665-3671.	<input type="checkbox"/>		
	52	ERI, et al., Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia, Scandinavian Journal of Clinical and Laboratory Investigation (1996) 56: 319-325.	<input type="checkbox"/>		
	53	FLORIDI, et al., Action of the Antitumor and Antispermatogetic Agent Lonidamine on Electron Transport in Ehrlich Ascites Tumor Mitochondria, Arch. Biochem Biophys (1983) 226(1):73-83.	<input type="checkbox"/>		
	54	FLORIDI, et al., Effect of Lonidamine on the Energy Metabolism of Ehrlich Ascites Tumor Cells, Cancer Res. (1981) 41:4661-4666.	<input type="checkbox"/>		
	55	FUKUTA, Y., et al., Z-350, a novel compound with alpha 1-adrenoceptor antagonistic and steroid 5 alpha-reductase inhibitory actions: pharmacological properties in vivo, J Pharmacol Exp Ther. (1999) 290(3):1013-8.	<input type="checkbox"/>		
	56	GATZEMEIER, et al., Phase III Trial With and Without Lonidamine in Non-Small Cell Lung Cancer, Seminars in Oncology (1991) 18(2) Suppl. 4:42-48.	<input type="checkbox"/>		
	57	GIRI, et al., Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia, Am J Pathol. (2001) 159:139-147.	<input type="checkbox"/>		
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/542,312
				Filing Date	July 15, 2005
				First Named Inventor	Tidmarsh, George
				Art Unit	1654
				Examiner Name	ABDEL A MOHAMED
Sheet	5	of	8	Attorney Docket Number	021305-003610US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	58	GRIMA, et al., Reversible Inhibition of Spermatogenesis in Rats Using a New Male Contraceptive 1-(2,4-Dichlorobenzyl)-Indazole-3-Carbohydrazide, Biol. of Reprod. (2001) 64:1500-1508.	<input type="checkbox"/>	
	59	Harrison's Principles of Internal Medicine 13th edition, volume 2, published by McGraw-Hill, Inc. (1994) pages 1862-1865.	<input type="checkbox"/>	
	60	HEYWOOD, et al., Toxicological Studies on 1-Substituted-Indazole-3-Carboxylic Acids, Chemotherapy (1981) 27 (Suppl. 2):91-97.	<input type="checkbox"/>	
	61	HIROSUMI, J., et al., FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) In vitro effects on human and animal prostatic enzymes, J Steroid Biochem Mol Biol. (1995) 52(4):357-63.	<input type="checkbox"/>	
	62	HIROSUMI, J., et al., FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (2) In vivo effects on rat and dog prostates, J Steroid Biochem Mol Biol. (1995) 52(4):365-73.	<input type="checkbox"/>	
	63	HUDSON, et al., Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells, Lab Invest. (2000) 80:1243-1250.	<input type="checkbox"/>	
	64	IANNIELLO, et al., Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial, Cancer (1996) 78(1):63-69.	<input type="checkbox"/>	
	65	International Search Report and Written Opinion for PCT/US2004/001141 (WO 2004/064735)	<input type="checkbox"/>	
	66	International Search Report and Written Opinion for PCT/US2004/001146 (WO 2004/064736)	<input type="checkbox"/>	
	67	ISAACS, et al., Etiology and disease process of benign prostatic hyperplasia, Prostate (1989) Suppl., 2:33-50.	<input type="checkbox"/>	
	68	KIRBY, R., The natural history of benign prostatic hyperplasia: what have we learned in the last decade?, Urology (2000) 56(5 suppl. 1):3-6 abstract only.	<input type="checkbox"/>	
	69	KURHANEWICZ, J., et al., Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy, Urology (1995) 45:459-466	<input type="checkbox"/>	
Examiner Signature				Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/542,312
				Filing Date	July 15, 2005
				First Named Inventor	Tidmarsh, George
				Art Unit	1654
				Examiner Name	ABDEL A MOHAMED
Sheet	6	of	8	Attorney Docket Number	021305-003610US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	70	LOBL, et al., Effects of Lonidamine (AF 1890) and Its Analogs on Follicle-Stimulating Hormone, Testosterone and Rat Androgen Binding Protein Concentrations in the Rat and Rhesus Monkey, Chemotherapy (1981) 27 (Suppl. 2):61-76.	<input type="checkbox"/>
	71	LOBL, 1-(2,4-Dichlorobenzyl)-1H-Indazole-3-Carboxylic Acid (DICA), an Exfoliative Antispermatic Agent in the Rat Arch, Andrology (1979) 2:353-63.	<input type="checkbox"/>
	72	MANSI, et al., A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer, Br. J. Cancer (1991) 64:593-597.	<input type="checkbox"/>
	73	MUNTZING, et al., Comparison and Significance of Respiration and Glycolysis of Prostatic Tissue from Various Species, J. Med. Primatol. (1975) 4:245-251.	<input type="checkbox"/>
	74	ORLANDI, et al., Lonidamine as a Modulator of Taxol Activity in Human Ovarian Cancer Cells: Effects on Cell Cycle and Induction of Apoptosis, Int. J. Can. (1998) 78:377-384.	<input type="checkbox"/>
	75	ORLANDI, et al., Potentiation of Cisplatin Cytotoxicity by Lonidamine in Primary Cultures of Human Ovarian Cancer, Anticancer Res. (1994) 14:1161-1164.	<input type="checkbox"/>
	76	PACINI, et al., FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results., Eur. J. Cancer (2000) 36:966-975.	<input type="checkbox"/>
	77	PAGGI, et al., The Role of Mitochondrial Hexokinase In Neoplastic Phenotype and Its Sensitivity to Lonidamine, Ann. NY Acad. Sci. (1988) 551:358-360.	<input type="checkbox"/>
	78	PORTALONE, et al., Treatment of Inoperable Non-Small Cell Lung Carcinoma Stage IIIB and IV with Cisplatin, Epidoxorubicin, Vindesine and Lonidamine: A Phase II Study, Tumori (1999) 85:239-42.	<input type="checkbox"/>
	79	POSSINGER, et al., Lonidamine in High-Risk Breast Cancer Patients, Sem. Onc. (1991) 18(2) Suppl. 4:58-61.	<input type="checkbox"/>
	80	PRICE, et al., Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs, Cancer Chemother. Pharmacol. (1996) 38:129-135.	<input type="checkbox"/>
	81	PRIVITERA, et al., Phase II double-blind randomized study of lonidamine and radiotherapy in epidermoid carcinoma of the lung, Radiother. Onc. (1987) 10:285-290.	<input type="checkbox"/>
Examiner Signature			Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/542,312
				Filing Date	July 15, 2005
				First Named Inventor	Tidmarsh, George
				Art Unit	1654
				Examiner Name	ABDEL A MOHAMED
Sheet	7	of	8	Attorney Docket Number	021305-003610US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	82	RAVAGNAN, et al., Lonidamine triggers apoptosis via a direct, BCL-2-inhibited effect on the mitochondrial permeability transition pore, Oncogene (1999) 18:2537-2546.	<input type="checkbox"/>	
	83	ROSSO, et al., Lonidamine in Metastatic Breast Cancer, Sem. Onc. (1991) 18(2) Suppl. 4:62-65.	<input type="checkbox"/>	
	84	ROTIN, et al., The Effect of the Drug Lonidamine on Chinese Hamster Ovary Cells In Vitro and on Experimental Tumors, Int. J. Radiation Oncology Biol. Phys. (1984) 10:1595-1598.	<input type="checkbox"/>	
	85	SAVINI, et al., In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines, Breast, Can. Res. Treat., 24:27-34 (1992).	<input type="checkbox"/>	
	86	SCARANTINO, et al., Lonidamine in Head and Neck Cancer: An Overview, Seminars in Onc. (1991) 18(2) Suppl. 4:28-32.	<input type="checkbox"/>	
	87	SCHIFFER, et al., Lonidamine in Malignant Brain Tumors, Seminars in Onc. (1991) 18(2) Suppl. 4:38-41.	<input type="checkbox"/>	
	88	SEGRE, et al., Pharmacokinetics of Lonidamine, Chemotherapy (1981) 27 (Suppl. 2):77-84.	<input type="checkbox"/>	
	89	SHIDAIFAT, et al., Gossypol arrests human benign prostatic hyperplastic cell growth at G0/G1 phase of the cell cycle, Anticancer Res. (1997) 17:1003-9.	<input type="checkbox"/>	
	90	SILVESTRINI, Lonidamine: An Overview, Seminars in Onc. (1991) 18(2) Suppl. 4:2-6.	<input type="checkbox"/>	
	91	Steadman's Medical Dictionary, 25th Edition, published by Williams & Wilkins, page 65, analog, (1990)	<input type="checkbox"/>	
	92	TEICHER, et al., Lonidamine: In Vitro/In Vivo Correlations, Eur. J. Cancer (1994) 30A(10):1411-1413.	<input type="checkbox"/>	
	93	TEICHER, et al., Modulation of Alkylating Agents by Lonidamine In Vivo, Seminars in Onc. (1991) 18(2) Suppl. 4:7-10.	<input type="checkbox"/>	
Examiner Signature				Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/542,312
				Filing Date	July 15, 2005
				First Named Inventor	Tidmarsh, George
				Art Unit	1654
				Examiner Name	ABDEL A MOHAMED
Sheet	8	of	8	Attorney Docket Number	021305-003610US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	94	VIEIRA, et al., Permeabilization of the mitochondrial inner membrane during apoptosis: Impact of the adenine nucleotide translocator, Cell Death and Differentiation (2000) 7:1146-1154.	<input type="checkbox"/>
	95	ZANIBONI, et al., Mitomycin-C and Iridomyrmecin as second-line therapy for colorectal cancer: a phase II study, Tumori (1995) 81(6):435-437.	<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.